首页> 外文期刊>Journal of Surgical Oncology >Predictors of cure after hepatic resection of colorectal liver metastases: an analysis of actual 5- and 10-year survivors.
【24h】

Predictors of cure after hepatic resection of colorectal liver metastases: an analysis of actual 5- and 10-year survivors.

机译:肝切除结直肠肝转移瘤后治愈的预测指标:对5年和10年实际存活者的分析。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND: Hepatic resection of colorectal liver metastases (CLM) is now regarded the standard of care. Evaluation of true long-term survivors will demonstrate the curative potential of this therapy with cure being defined as actual 10-year survival versus a satisfactory oncological outcome of 5-year survival. Limited data exists on outcomes of patients beyond 5 years. Studying the rates of cure and predictive factors for cure are essential to define the true benefit of this therapy. METHODS: Retrospective review of a prospectively maintained hepatobiliary surgical database was performed on patients who underwent hepatic resection of CLM between 1991 and 2005 with a minimum of 5-year follow-up. Survival was calculated from the time of surgery using the Kaplan-Meier method. RESULTS: There were 455 consecutive patients with a minimum of 5-year follow-up. The actuarial median overall survival was 33 months (95% CI, 29-37%), actuarial 5-, and 10-year survival rates were 34% and 25%, respectively. Hundred twenty four patients were identified as actual 5-year survivors (27%) with their actuarial median overall survival being 11.1 years, actuarial 10-year survival rate of 59%, and a median disease-free survival of 4.9 years. Patients requiring subsequent treatment of modern systemic chemotherapy for post-resection recurrence (P = 0.003) was a negative predictors of cure from multivariate analysis. CONCLUSION: This study demonstrate that approximately one in three patients undergoing resection for CLM will become actual 5-year survivors from which approximately half will go on to survive 10-years and be cured of CLM.
机译:背景:大肠肝转移(CLM)的肝切除术现在被认为是护理的标准。对真正长期存活者的评估将证明这种疗法的治愈潜力被定义为实际的10年生存率与5年生存率的令人满意的肿瘤学结果。关于5年以上患者结局的数据有限。研究治愈率和治愈预测因素对于定义该疗法的真正益处至关重要。方法:回顾性回顾性分析1991年至2005年间接受CLM肝切除术且至少随访5年的患者的前瞻性维持的肝胆外科数据库。使用Kaplan-Meier方法从手术时间计算存活率。结果:连续455例患者接受了至少5年的随访。精算中位总体生存期为33个月(95%CI,29-37%),精算5年和10年生存率分别为34%和25%。一百二十四名患者被确定为实际的五年生存者(27%),他们的精算中位数总生存期为11.1年,精算10年生存率为59%,无疾病生存期的中位数为4.9年。从多因素分析来看,需要现代全身化疗后续治疗以切除后复发的患者(P = 0.003)是治愈的阴性指标。结论:这项研究表明,接受CLM切除的患者中约有三分之一将成为真正的5年生存者,其中约一半将继续生存10年并治愈CLM。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号